MedTrace Logo

HVNI Ambulation Feasibility Study

NCT03885726 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2020-10-19

Study results available
· View outcomes & findings →

Summary

The pilot/feasibility study evaluates the ability of High Velocity Nasal Insufflation (HVNI) therapy to facilitate ambulation and mobilization in patients experiencing shortness of breath, as compared to simple oxygen therapy.

Conditions

  • Respiratory Insufficiency
  • Dyspnea

Interventions

DEVICE

Precision Flow Plus

High velocity nasal insufflation

DEVICE

Treatment as Usual

Conventional therapy per institution

Sponsors & Collaborators

  • Knox Community Hospital

    collaborator OTHER

  • Riverside Medical Center

    collaborator OTHER

  • Midwest Chest Consultants

    collaborator OTHER

  • Vapotherm, Inc.

    lead INDUSTRY

Principal Investigators

  • Shailesh Patel, MD · Knox Community Hospital

  • Thomas M Siler, MD · Midwest Chest Consultants

  • Paragkumar Amin, MD · Riverside Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-21
Primary Completion
2019-02-28
Completion
2019-03-11
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03885726 on ClinicalTrials.gov